Argus downgraded Roche to Hold from Buy. The company’s earnings and revenue prospects offer limited growth potential, and while Roche has a strong line-up of blockbuster products, many of which were acquired years ago through its purchase of Genentech, some of these drugs are maturing and face competition from biosimilars, the analyst tells investors in a research note. Argus adds it would consider upgrading the stock in the event of sustained margin growth, the launch of a new blockbuster product, or signs that earnings or revenue growth will begin to accelerate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- Biotech Alert: Searches spiking for these stocks today
- Codexis, Roche in licensing deal for newly engineered double-sranded DNA Ligase
- Roche seeing interest in Esbriet, weighing potential sale, Bloomberg says
- New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
- Roche price target lowered to CHF 210 from CHF 230 at JPMorgan
